Company intelligence / Profile preview

biomodal

Saffron Walden / Little Chesterford, Essex, United Kingdombiomodal.com ↗

Ownership: Private
Development stage: Commercial

Overview

biomodal develops advanced multiomic sequencing technologies that enable simultaneous capture of genetic and epigenetic information from a single low-input DNA sample. Their flagship product, the duet multiomics solution, provides highly accurate phased sequencing data without harsh chemical treatments or complex bioinformatics. This platform supports researchers studying cancer biology, neurodegeneration, ageing processes, and other areas by revealing dynamic regulatory functions across the genome.

Therapeutic areas: OncologyNeurologyOther
Modalities: Multiomics sequencing technologyGenetic sequencingEpigenetic analysisSingle-base-resolution phased sequencing
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on biomodal.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on biomodal.

Explore the full profile